FAQs

Update on Management of Neonatal Hypoglycemia

Presentation by Dr. Jane Harding, Dr. Jane Alsweiler and Dr. Chris McKinlay

During this webinar you will learn about:

    • Pathophysiology of neonatal hypoglycemia
    • Which babies are at risk
    • Long-term effects of hypoglycemia on neurodevelopment
    • The evidence for screening babies for neonatal hypoglycemia
    • Treatment options for babies with neonatal hypoglycemia
    • Prevention options for babies at risk of hypoglycemia

 

There is a Q&A session at the end of the presentation.

 

 

About the Speakers

 

Jane E. Harding, DNZM, MBChB, DPhil, FRACP, FRSNZ
Jane Harding is a University of Auckland Distinguished Professor, and a researcher in the LiFEPATH research group of the University’s Liggins Institute. Professor Harding practised as specialist neonatologist at National Women’s Hospital, Auckland, and has been Deputy Vice-Chancellor (Research) at the University of Auckland. Her on-going research concerns the role of nutrition and growth factors in the regulation of growth before and after birth, blood glucose regulation in the newborn, and the long-term consequences of treatments given around the time of birth.

 

 

 

Jane Alsweiler, MBChB, FRACP, PhD
Jane Alsweiler is an Associate Professor in the Dept. of Paediatrics: Child and Youth Health, University of Auckland and works clinically as a neonatal paediatrician in the neonatal intensive care unit at Auckland City Hospital. She is the chair of the PSANZ policy committee and the neonatal representative on the PSANZ Board. Her current research interests focus on neonatal glucose homeostasis and growth, including long-term consequences of hypo- and hyperglycaemia and late preterm birth.

 

 

 

Chris McKinlay, PhD, MBChB, DipProfEthics
Chris McKinlay is a neonatologist at Kidz First Hospital, Counties Manukau, and Senior Lecturer in perinatal health, Liggins Institute, University of Auckland, New Zealand. His research focuses on early life interventions for improving long-term metabolic, neurodevelopmental and respiratory health outcomes of at-risk infants.